RMgmDB - Rodent Malaria genetically modified Parasites

Back to search results

Summary

RMgm-4871
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_0304800; Gene model (P.falciparum): PF3D7_0207400; Gene product: serine repeat antigen 7 (serine repeat antigen 7, SERA7, SERA4)
Transgene
Transgene not Plasmodium: GFP (gfp-mu3)
Promoter: Gene model: PBANKA_1133300; Gene model (P.falciparum): PF3D7_1357100; Gene product: elongation factor 1-alpha (eef1a)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
Phenotype Liver stage;
Last modified: 23 September 2020, 14:04
  *RMgm-4871
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 32956401
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 507cl1 (RMgm-7)
Other information parent lineP.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line which expresses GFP under control of a constitutive promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 16242190).
The mutant parasite was generated by
Name PI/ResearcherPutrianti ED, Heussler V, Ingmundson A
Name Group/DepartmentParasitology Unit
Name InstituteMax Planck Institute for Infection Biology
CityBerlin
CountryGermany
Name of the mutant parasite
RMgm numberRMgm-4871
Principal namePbsera4(-)
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot different from wild type
Fertilization and ookineteNot different from wild type
OocystNot different from wild type
SporozoiteNot different from wild type
Liver stageProlonged prepatent period (2 days) of blood stage infection after intravenous infection of mice with 10(5) sporozoites.
Pbsera4(-) parasites reached levels equivalent to wildtype parasites in livers of infected animals 48 hours after infection. The parasite burden in livers infected by wildtype parasites drops by 72 hours after infection due to egress and merozoite release. Although the appearance of Pbsera4(-) parasites in the blood of sporozoite-infected animals is delayed, the Pbsera4(-) parasites do not appear to be retained in the liver at 72 hours after infection.
When Huh7 cells were infected, Pbsera4(-) sporozoites developed into exo-erythrocytic forms (EEF) in numbers similar to those formed by wildtype sporozoites. Pbsera4(-)-infected cultures generated approximately half the numbers of merosomes produced by wildtype-infected cultures. When equal numbers of wildtype or Pbsera4(-) merosomes produced by cultured cells were injected into mice, all mice developed a blood-stage infection, indicating that the Pbsera4(-) liver-stage merozoites that are generated are as capable of infecting red blood cells and establishing a blood-stage infection as wildtype merozoites.
Together, these data indicate that liver-stage Pbsera4(-) parasites are released inefficiently from infected cells, but that they are infectious to red blood cells.
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of SERA4 and expresses GFP under the constitutive eef1a promoter

Protein (function)
The Plasmodium berghei PbSERA4 (PBANKA_0304800) gene encodes a cysteine-type SERA and is conserved and syntenic across the primate and rodent Plasmodium species. The predicted orthologue of PbSERA4 in Plasmodium falciparum is PfSERA7 (PF3D7_0207400), and the proteins encoded by these genes are 44% identical and 57% similar. Within the signature papain family cysteine protease domain (PFAM: PF00112), PbSERA4 and PfSERA7 share 66% amino acid identity and include the strictly conserved catalytic residues, i.e. an amino-terminal glutamine, the catalytic cysteine residue, a central histidine, and a carboxy-terminal asparagine.

Phenotype
Normal blood stage and mosquito stage development

Prolonged prepatent period (2 days) of blood stage infection after intravenous infection of mice with 10(5) sporozoites. 
Pbsera4(-) parasites reached levels equivalent to wildtype parasites in livers of infected animals 48 hours after infection. The parasite burden in livers infected by wildtype parasites drops by 72 hours after infection due to egress and merozoite release. Although the appearance of Pbsera4(-) parasites in the blood of sporozoite-infected animals is delayed, the Pbsera4(-) parasites do not appear to be retained in the liver at 72 hours after infection.
When Huh7 cells were infected, Pbsera4(-) sporozoites developed into exo-erythrocytic forms (EEF) in numbers similar to those formed by wildtype sporozoites. Pbsera4(-)-infected cultures generated approximately half the numbers of merosomes produced by wildtype-infected cultures. When equal numbers of wildtype or Pbsera4(-) merosomes produced by cultured cells were injected into mice, all mice developed a blood-stage infection, indicating that the Pbsera4(-) liver-stage merozoites that are generated are as capable of infecting red blood cells and establishing a blood-stage infection as wildtype merozoites.
Together, these data indicate that liver-stage Pbsera4(-) parasites are released inefficiently from infected cells, but that they are infectious to red blood cells.

Additional information
To examine protein expression and assess the localization of PbSERA4, we generated a transgenic P. berghei ANKA line that expresses fluorescently tagged PbSERA4 from the native PbSERA4 promoter (RMgm-4872). We detected PbSERA4-mCherry signal in late asexual blood stages and gametocytes, and we could observe red fluorescence throughout exflagellation of male gametes. We failed to detect a red fluorescent signal in PbSERA4-mCherry sporozoites isolated from mosquito midguts or salivary glands despite the presence of PbSERA4 transcripts. No mCherry signal could be detected in early liver-stage P. berghei. However fluorescent protein expression in both lines is evident later in the liver stage. PbSERA4-mCherry could be detected 48 hours after infection of cultured cells with PbSERA4-mCherry sporozoites. The PbSERA4-mCherry signal progressively increased, and late liver schizonts and liver merozoites exhibited bright fluorescence.

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_0304800
Gene Model P. falciparum ortholog PF3D7_0207400
Gene productserine repeat antigen 7
Gene product: Alternative nameserine repeat antigen 7, SERA7, SERA4
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationTransgenic P. berghei lines were generated as described previously. For mCherry tagging, the PbSERA4 locus was amplified with primers mCherry-SERA4for and mCherry-SERA4rev and integrated into B3D+mCherry in frame with the mCherry coding sequence. For targeted disruption of PbSERA4, a replacement vector was generated through amplification of genomic regions flanking PbSERA4 using primers SERA4rep1for and SERA4rep2rev or SERA4rep3for and SERA4rep4rev and cloned into b3D.DT^H.^D flanking the Tgdhfr/TS expression cassette
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameGFP (gfp-mu3)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitegfp (FACS)
Promoter of the selectable markereef1a
Selection (positive) procedureFACS (flowsorting)
Selection (negative) procedureNo
Additional remarks genetic modificationThe GFP gene (1 copy) has been inserted into the 230p locus (PBANKA_030600) by double cross-over integration.
Additional remarks selection procedureThis reporter mutant expressing GFP does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1133300
Gene Model P. falciparum ortholog PF3D7_1357100
Gene productelongation factor 1-alpha
Gene product: Alternative nameeef1a
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4